$EVMN

Morgan Stanley initiated coverage on Evommune Inc (NYSE:EVMN) with an Overweight rating and a $26.00 price target, citing potential in its EVO301 drug for atopic dermatitis. The company's stock is down 74% over the past year, trading at $5.27. Analysts have mixed reactions following recent trial results, with some maintaining positive outlooks despite setbacks. The atopic dermatitis market is expected to grow to $26 billion by 2030, according to Morgan Stanley.

UBS initiated coverage on Evommune, Inc. with a Hold rating and a $8.00 price target. The analyst consensus is Strong Buy with an average target of $22.40. The company reported a Q2 GAAP net loss of $32.25M, up from $13.57M last year.

Evommune (NYSE:EVMN) presented Phase 2a trial data for EVO301 in atopic dermatitis, showing a 55% reduction in EASI score vs. 22% on placebo. The trial met its primary endpoint, with significant improvements observed at multiple time points. The company plans to initiate a Phase 2b trial in mid-2027.

Evommune, Inc. (EVMN) filed an SEC Form 8-K — Regulation FD Disclosure. Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress - Presentation highlights EVO301’s clear therapeutic signal, favorable safety and tolerability profile, and reinforces

Evommune (EVMN) announced positive Phase 2a data for EVO301 in treating moderate-to-severe atopic dermatitis. The results will be presented at the European Academy of Dermatology & Venereology Congress on October 1, 2026, highlighting EVO301's potential as a broad-spectrum inflammatory treatment.

Evommune, Inc. (EVMN) filed an SEC Form 8-K — Regulation FD Disclosure. Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress Palo Alto, Calif., and New York, September 23, 2026 – Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical

Evommune, Inc. (EVMN) filed an SEC Form 8-K — Regulation FD Disclosure. Evommune Corporate Presentation September 2026 © Evommune, Inc. Disclaimers This presentation has been prepared by Evommune, Inc. (“we”, “us” or “our”) and contains forward-looking statements, including: statements about our expectations regarding the potential benefits, clinical

Evommune's (EVMN) stock fell 53% after its eczema treatment failed midstage trials, following a previous failure in treating hives. The company continues testing EVO756 for migraine prevention and has another eczema treatment, EVO301, in development.

US equity futures fell as Brent crude oil topped $100, pushing 10-year Treasury yields above 4.81%. Meta (META) rose 5% on strong AI usage, while other Mag 7 stocks traded mixed. Braze (BRZE) dropped 11% on weak earnings forecasts, and ServiceTitan (TTAN) fell 17% on revenue concerns. Chime (CHYM) gained 9% after acquiring Stride Bank. Oil prices surged after US strikes on Iranian tankers, and Treasury Secretary Scott Bessent challenged traders on yen strength. Barclays raised its S&P 500 target

Evommune Inc (EVMN) shares dropped 27% after its EVO756 drug failed to meet primary and secondary endpoints in a Phase 2b trial for atopic dermatitis. The trial involved 121 adults over 12 weeks. Evommune will not advance EVO756 for this indication but will continue its development for migraine prophylaxis. The company plans to advance EVO301 for atopic dermatitis, with a Phase 2b trial expected in mid-2027. Evommune reports a strong balance sheet supporting operations into 2029.